|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Dental caries
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide analysis of dental caries and periodontitis combining clinical and self-reported data.
|
31235808 |
2019 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Motion Sickness
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic variants associated with motion sickness point to roles for inner ear development, neurological processes and glucose homeostasis.
|
25628336 |
2015 |
|
Obesity
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
A genome-wide association meta-analysis identifies new childhood obesity loci.
|
22484627 |
2012 |
|
Obesity
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
A genome-wide association meta-analysis identifies new childhood obesity loci.
|
22484627 |
2012 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
The peptides or proteins encoded by ncRNA (HOXB-AS3, encoded by long ncRNA [lncRNA]; FBXW7-185aa, PINT-87aa, and SHPRH-146aa, encoded by circular RNA [circRNA]; and miPEP-200a and miPEP-200b, encoded by primary miRNAs) have been shown to be critical players in cancer development and progression, through effects upon the regulation of glucose metabolism, the epithelial-to-mesenchymal transition, and the ubiquitination pathway.
|
31526596 |
2019 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
This study uncovers a promoting role of HOXB-AS3 in myeloid malignancies and identifies the prognostic value of HOXB-AS3 expression in AML and MDS patients, particularly in the lower-risk group.
|
31234830 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.020 |
Biomarker
|
disease |
BEFREE |
We show that HOXB-AS3 regulates the proliferative capacity of NPM1mut AML blasts in vitro and in vivo.
|
31767858 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Further, we retrospectively analyzed the HOXB-AS3 expression in 193 patients with AML and 157 with MDS by microarray analysis, and evaluated its clinical importance.
|
31234830 |
2019 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Overexpression of long noncoding RNA HOXB-AS3 indicates an unfavorable prognosis and promotes tumorigenesis in epithelial ovarian cancer via Wnt/β-catenin signaling pathway.
|
31337688 |
2019 |
|
Epithelial ovarian cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found that in both EOC cell lines and tissues, HOXB-AS3 expression was significantly up-regulated, and its high expression was an independent prognostic marker of poor outcome for EOC patients.
|
31337688 |
2019 |
|
Tumor Cell Invasion
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Furthermore, we validated that down-regulated HOXB-AS3 attenuated the activity of Wnt/β-catenin signaling to suppress the invasion, migration and proliferation of EOC cells.
|
31337688 |
2019 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
The peptides or proteins encoded by ncRNA (HOXB-AS3, encoded by long ncRNA [lncRNA]; FBXW7-185aa, PINT-87aa, and SHPRH-146aa, encoded by circular RNA [circRNA]; and miPEP-200a and miPEP-200b, encoded by primary miRNAs) have been shown to be critical players in cancer development and progression, through effects upon the regulation of glucose metabolism, the epithelial-to-mesenchymal transition, and the ubiquitination pathway.
|
31526596 |
2019 |
|
Childhood Myelodysplastic Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome.
|
31234830 |
2019 |
|
MYELODYSPLASTIC SYNDROME
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Further, we retrospectively analyzed the HOXB-AS3 expression in 193 patients with AML and 157 with MDS by microarray analysis, and evaluated its clinical importance.
|
31234830 |
2019 |
|
Adult Myelodysplastic Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome.
|
31234830 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found that in both EOC cell lines and tissues, HOXB-AS3 expression was significantly up-regulated, and its high expression was an independent prognostic marker of poor outcome for EOC patients.
|
31337688 |
2019 |
|
Liver neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
lncRNA HOXB-AS3 promotes hepatoma by inhibiting p53 expression.
|
30402841 |
2018 |
|
Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The expression of HOXB-AS3 in tumor tissues and adjacent tissues of hepatocellular carcinoma was detected by quantitative real time-polymerase chain reaction (qRT-PCR), and the relationship between the expression of HOXB-AS3 and tumor tissues was analyzed.
|
30402841 |
2018 |
|
Liver carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The results of qRT-PCR showed that the expression of HOXB-AS3 was significantly higher in cancerous tissues of patients with hepatocellular carcinoma than in adjacent tissues.
|
30402841 |
2018 |
|
Malignant tumor of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
A Peptide Encoded by a Putative lncRNA HOXB-AS3 Suppresses Colon Cancer Growth.
|
28985503 |
2017 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our study indicates that the loss of HOXB-AS3 peptide is a critical oncogenic event in CRC metabolic reprogramming.
|
28985503 |
2017 |
|
Colon Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
A Peptide Encoded by a Putative lncRNA HOXB-AS3 Suppresses Colon Cancer Growth.
|
28985503 |
2017 |